Litigation Details for Allergan Sales, LLC v. Ajanta Pharma Ltd. (D. Del. 2019)
✉ Email this page to a colleague
Allergan Sales, LLC v. Ajanta Pharma Ltd. (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-07-02 |
| Court | District Court, D. Delaware | Date Terminated | 2020-01-02 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 6,545,040 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan Sales, LLC v. Ajanta Pharma Ltd.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Allergan Sales, LLC v. Ajanta Pharma Ltd. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-07-02 | 1 | Complaint | infringement of U.S. Patent No. 6,545,040 (“the ’040 Patent”) under the patent laws of the United States…Extending Patent Term Under 35 U.S.C. § 156. With the patent term extension, the ’040 Patent will expire…expiration of the ’040 Patent covering Bystolic® and its use. A copy of the ’040 Patent is attached as Exhibit…, the United States Patent and Trademark Office (“USPTO”) issued the ’040 Patent to Janssen Pharmaceutica…amendments have been made to the patent,” and that the “patentability of claims 1–6 is confirmed.” | External link to document |
| 2019-07-02 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,545,040 B1. (lak) (Entered:…2019 2 January 2020 1:19-cv-01249 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
